𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer

✍ Scribed by Mohammed A. Aleskandarany; Andrew R. Green; Emad A. Rakha; Rabab A. Mohammed; Somaia E. Elsheikh; Desmond G. Powe; Emma C. Paish; R. Douglas Macmillan; Steve Chan; Samreen I. Ahmed; Ian O. Ellis

Publisher
John Wiley and Sons
Year
2010
Tongue
French
Weight
218 KB
Volume
126
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Accurate predictive markers of chemotherapeutic response in early breast cancer are still lacking. The role of tumour growth fraction as a predictor of response to chemotherapy was assessed in early breast cancer. In this study, immunohistochemical expression of MIB1 was studied in a well‐characterised series of early (Stages I and II) node‐negative breast carcinoma cases (n = 100) with long‐term follow‐up that have received adjuvant chemotherapy (cyclophosphamide/methotrexate/5‐fluorouracil regimen). In addition, 728 cases who did not receive adjuvant chemotherapy were used as a control group. Increased tumour growth fraction was associated with a better response to adjuvant chemotherapy in terms of longer breast cancer specific survival and disease‐free interval [hazard ratio (HR) = 0.354, 95% CI = 0.177–0.688, p = 0.003 and HR = 0.396, 95% CI = 0.205–0.768, p = 0.006, respectively]. In contrast to the control group, patients with high growth fraction tumour (>70%) showed an excellent outcome with infrequently reported events during the period of follow‐up. Importantly, patients with a low growth fraction (≤10%) showed frequent recurrences and shorter survival time with outcome comparable to those of high growth fraction who did not receive chemotherapy. Therefore, tumour growth fraction can be used to assign patients into distinct groups showing differential response to adjuvant chemotherapy. Patients with a high growth fraction appear to be ideal candidates for adjuvant chemotherapy while those with low growth fraction are less likely to benefit and are prone to the potential serious side effects of adjuvant chemotherapy.

📜 SIMILAR VOLUMES

Osteoblastic metastatic disease as a the
Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer
✍ Angela L. Demartini; Aman U. Buzdar; George R. Blumenschein 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB

Included in this study were 43 breast cancer patients treated with adjuvant chemotherapy who presented metastasis only in bone. Forty-two percent had metastasis during chemotherapy, and 58% had metastasis after the completion of chemotherapy. In 66% of the patients, the lesions were osteolytic. Twen

p53 mutations as a possible predictor of
p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas
✍ Jean Benhattar; Jean-Philippe Cerottini; Emilia Saraga; Geneviève Metthez; Jean- 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 310 KB 👁 2 views

Although intrahepatic infusion therapy with 5-fluorouracil for unresectable colorectal liver metastases may lead to improved overall survival for some patients, it is not clear why a response is not observed in others. Gene alterations in oncogenes or tumor-suppressor genes are critical events in tu

Sequential assessment of multidrug resis
Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy
✍ Sylvie Chevillard; Pierre Pouillart; Chérif Beldjord; Bernard Asselain; Philippe 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 698 KB

The authors examined the relevance of S-phase fraction (SPF) and multidrug resistance (MDR) phenotype as predictive tests of breast cancer response in a series of patients treated by conventional doses of neoadjuvant chemotherapy with (FAC) or without (FTC) doxorubicin. ## METHODS. Fine needle sa

MRI measurements of tumor size and pharm
MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy
✍ Hon J. Yu; Jeon-Hor Chen; Rita S. Mehta; Orhan Nalcioglu; Min-Ying Su 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB

## Abstract ## Purpose To investigate the value of using changes in three parameters (tumor size, transfer constant (K^trans^), and rate constant (k~ep~)) obtained after the first treatment‐cycle in predicting the final clinical response after two to four cycles of neoadjuvant anthracycline and cy